Denali Therapeutics Inc. (DNLI) News
Filter DNLI News Items
DNLI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DNLI News Highlights
- DNLI's 30 day story count now stands at 6.
- Over the past 21 days, the trend for DNLI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about DNLI are SRPT and VRNA.
Latest DNLI News From Around the Web
Below are the latest news stories about DENALI THERAPEUTICS INC that investors may wish to consider to help them evaluate DNLI as an investment opportunity.
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the DayFluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article. |
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024. |
40 Cities with the Highest Life Expectancy in the USIn this article, we look at 40 Cities With The Highest Life Expectancy In The US. You can skip our detailed analysis on companies that are working on longevity enhancement and improved health facilities by heading over directly to the 10 Cities With The Highest Life Expectancy In The US. Life expectancy of a newborn […] |
Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect?The consensus price target hints at a 123.4% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Why Is Denali Therapeutics Inc. (DNLI) Down 5.2% Since Last Earnings Report?Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
After losing 39% in the past year, Denali Therapeutics Inc. (NASDAQ:DNLI) institutional owners must be relieved by the recent gainKey Insights Given the large stake in the stock by institutions, Denali Therapeutics' stock price might be vulnerable... |
Wall Street Analysts See a 163.82% Upside in Denali Therapeutics Inc. (DNLI): Can the Stock Really Move This High?The consensus price target hints at a 163.8% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsFlagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo |
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue EstimatesDenali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 13.25% and 88.33%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsSOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights. “Exciting progress in the field related to treating neurodegenerative di |